HLA G Antibody (5A6G7) [Janelia Fluor® 549]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-44924JF549
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, ELISA, Flow (Intracellular), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Western Blot
Label
Janelia Fluor 549
Antibody Source
Monoclonal Mouse IgG1 Clone # 5A6G7
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to ovalbumin.
Specificity
The antibody 5A6G7 allows to discriminate between soluble HLA-G protein yielded by shedding from membrane-bound HLA-G forms that do not contain the intron 4-encoded epitope and soluble HLA-G5/HLA-G6 produced from intron 4-retaining alternatively spliced mRNAs. HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Theoretical MW
39 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Applications for HLA G Antibody (5A6G7) [Janelia Fluor® 549]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow (Intracellular)
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Frozen
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: HLA-G
Discovered in cytotrophoblasts, HLA-G is involved in fetal maternal immune tolerance and some studies have linked its downregulation with severe preeclampsia (3). HLA-G mediated immune suppression works by impeding cell proliferation, differentiation, cytotoxicity, cytokine secretion and chemotaxis; and activation of regulatory cells and MDSCs or M2 type macrophage. HLA-G is constitutively expressed in immune-privileged sites such as pancreatic islets, mesenchymal stem cells (MSCs) and the cornea. Upregulation of HLA-G occurs in pathological states including cancer, allo-transplantations, viral infections, autoimmune and inflammatory diseases (4). In cancer, HLA-G expression is induced by hypoxia and has been correlated with advanced tumor stage, tumor metastasis, and poor therapeutic response and survival. HLA-G is an attractive tumor associated-antigen (TAA) for immunotherapy and is considered a major immune checkpoint (ICP).
References
1. Loustau, M., Anna, F., Drean, R., Lecomte, M., Langlade-Demoyen, P., & Caumartin, J. (2020). HLA-G Neo-Expression on Tumors. Front Immunol, 11:1685. PMID: 32922387
2. Lin A, Yan WH. (2018) Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges. Front Immunol. 9:2164. PMID: 30319626
3. Djurisic S, Hviid TV. (2014) HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia. Front Immunol. 5:652. PMID: 25566263
4. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 98(21):12150-12155. PMID: 11572934
Long Name
Major Histocompatibility Complex, Class I, G
Alternate Names
HLA G, HLA-6.0, HLAG, MHC Class I Antigen G, MHC-G
Gene Symbol
HLA-G
Additional HLA-G Products
Product Documents for HLA G Antibody (5A6G7) [Janelia Fluor® 549]
Product Specific Notices for HLA G Antibody (5A6G7) [Janelia Fluor® 549]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...